Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re: Ozempic (Semaglutide) Patent Litigation
Case Number:
1:22-md-03038
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Multi Party Litigation:
Multi-district Litigation
Judge:
Firms
- Heyman Enerio
- Morris James
- Morris Nichols
- Richards Layton
- Shaw Keller
- Stamoulis & Weinblatt
- Steptoe & Johnson PLLC
- Young Conaway
Companies
- Alvogen Group Inc.
- Dr. Reddy's Laboratories Ltd.
- Novo Nordisk A S
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Pharmaceuticals Inc.
Sectors & Industries:
-
October 07, 2024
Mylan, Novo Nordisk Settle Ozempic Patent Dispute
Mylan Pharmaceuticals and Novo Nordisk have asked the Patent Trial and Appeal Board to terminate Mylan's request to review whether a patent covering Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic holds up, telling the board the two sides have resolved their dispute.
-
August 02, 2024
PTAB Told To Punish Mylan For Allegedly Breaking Fintiv Vow
Novo Nordisk is urging the Patent Trial and Appeal Board to sanction Mylan for pursuing claims to invalidate a patent covering the blockbuster diabetes and weight loss drug Ozempic in Delaware district court, despite an explicit promise not to do so.
-
October 04, 2023
Never Mind: Ozempic Patents Not Fully In The Clear At PTAB
The Patent Trial and Appeal Board on Wednesday granted Mylan's request to review whether a patent covering Novo Nordisk's blockbuster drug Ozempic holds up, just two days after clearing the Danish company from challenges to related patents.
-
October 03, 2023
Novo Nordisk Dodges PTAB Review On Lucrative Ozempic IP
The Patent Trial and Appeal Board will not review whether a pair of Novo Nordisk patents covering its blockbuster diabetes and weight-loss drug Ozempic should be invalidated.